The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study

We observed a substantial reduction in cervical cancer and incidence of CIN3 in young women after the introduction of the HPV immunisation programme in England, especially in individuals who were offered the vaccine at age 12–13 years. The HPV immunisation programme has successfully almost eliminated cervical cancer in women born since Sept 1, 1995.

Read the full article here

Source: The Lancet

Categories: Healthcare Professionals, Latest Headlines

Tweets with this article

Dominic King

Drop the mic ending ‘The HPV immunisation programme has successfully almost eliminated cervical cancer in women born since Sept 1, 1995’. Medical science and its effective translation can do wonderful things https://t.co/y9crSgf4nC

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

This past month, we saw the publication of the final, pre-specified analysis of the PROpel study, assessing abiraterone and olaparib in combination. This study was…

john doe 5 October 6, 2023

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

The third trial to report in this space was TALAPRO-2. Dr. Aggarwal presented the all-comers cohort from this trial at ASCO-GU this spring with the…

john doe 5 October 6, 2023

A pandemic playbook

A review of my book published in the Lancet.

john doe 5 October 5, 2023

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

There is a paucity of effective systemic therapy options for patients with advanced, chemotherapy-refractory colorectal cancer. We aimed to evaluate the efficacy and safety of…

john doe 5 June 21, 2023

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study

The TRANSCEND CLL 004 trial represents the most promising data of CAR T-cell therapy – liso-cel – in chronic lymphocytic leukemia (CLL), a disease where…

Blood Cancer Talks June 9, 2023

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study

Patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma for whom treatment has failed with both Bruton tyrosine kinase (BTK) inhibitor and…

Eddie Cliff June 7, 2023

Related Articles